| Literature DB >> 21350793 |
Fengpeng Li1, Enchao Qiu, Zhao Dong, Ruozhuo Liu, Shiwen Wu, Shengyuan Yu.
Abstract
A rat cortical spreading depression (CSD) model was established to explore whether cerebral mitochondria injury was induced by CSD under both normoxic and hypoxic conditions and whether flunarizine had a protective effect on cerebral mitochondria. SD rats, which were divided into seven groups, received treatment as follows: no intervention (control Group I); 1 M NaCl injections (Group II); 1 M KCl injections (Group III); intraperitoneal flunarizine (3 mg/kg) 30 min before KCl injections (Group IV); 14% O(2) inhalation before NaCl injections (Group V); 14% O(2) inhalation followed by KCl injections (Group VI); 14% O(2) inhalation and intraperitoneal flunarizine followed by KCl injections (Group VII). Following treatment, brains were removed for the analysis of mitochondria transmembrane potential (MMP) and oxidative respiratory function after recording the number, amplitude and duration of CSD. The duration of CSD was significantly longer in Group VI than that in Group III. The number and duration of CSD in Group VII was significantly lower than that in Group VI. MMP in Group VI was significantly lower than that in Group III, and MMP in Group VII was significantly higher than that in Group VI. State 4 respiration in Group VI was significantly higher than that in Group III, and state 3 respiration in Group VII was significantly higher than that in Group VI. Respiration control of rate in Group VII was also significantly higher than that in Group VI. Thus, we concluded that aggravated cerebral mitochondria injury might be attributed to CSD under hypoxic conditions. Flunarizine can alleviate such cerebral mitochondria injury under both normoxic and hypoxic conditions.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21350793 PMCID: PMC3055997 DOI: 10.1007/s10194-011-0300-1
Source DB: PubMed Journal: J Headache Pain ISSN: 1129-2369 Impact factor: 7.277
Fig. 1The manifestation of CSD
The number and amplitude of CSD (mean ± SD)
| Group | Number | Amplitude (mv) |
|---|---|---|
| Group III | 9.25 ± 3.81 | 14.54 ± 6.05 |
| Group IV | 3.88 ± 4.05** | 11.75 ± 4.13* |
| Group VI | 8.63 ± 2.67 | 16.91 ± 6.12 |
| Group VII | 5.00 ± 3.16*,Δ | 15.29 ± 3.39 |
* P < 0.05 versus Group III; ** P < 0.01 versus Group III; Δ P < 0.05 versus Group VI
The duration of CSD in each group
| Group | Duration (s) |
|---|---|
| Group III | 59 (49.5–72.5) |
| Group IV | 55 (50–62)* |
| Group VI | 75 (64–92)** |
| Group VII | 65 (58.5–79)**,ΔΔ |
The values are median (25% quartile–75% quartile)
* P < 0.05 versus Group III; ** P < 0.01 versus Group III; ΔΔ P < 0.01 versus Group VI
Mitochondrial oxidative respiratory function (mean ± SD)
| Group | ST3 (nmol/min/mg pro) | ST4 (nmol/min/mg pro) | RCR |
|---|---|---|---|
| Group I | 103.05 ± 21.73 | 18.29 ± 7.15 | 6.18 ± 2.02 |
| Group II | 102.27 ± 8.88 | 18.36 ± 5.66 | 6.04 ± 2.05 |
| Group III | 82.47 ± 24.00 | 29.26 ± 12.12 | 3.14 ± 1.46 |
| Group IV | 89.39 ± 33.95 | 29.16 ± 17.61 | 4.54 ± 1.06 |
| Group V | 93.35 ± 22.02 | 43.05 ± 16.68**,ΔΔ | 3.30 ± 1.44 |
| Group VI | 61.73 ± 23.44**,▲▲ | 45.66 ± 18.11**,◊ | 1.36 ± 0.35** |
| Group VII | 86.28 ± 19.28☆ | 37.62 ± 11.19** | 2.34 ± 0.36*,☆☆ |
* P < 0.05 versus Group I; ** P < 0.01 versus Group I; ΔΔ P < 0.01 versus Group II; ◊ P < 0.05 versus Group III; ▲▲ P < 0.01 versus Group V; ☆ P < 0.05 versus Group VI; ☆☆ P < 0.01 versus Group VI
MMP in each group (mean ± SD)
| Group | MMP (mv) |
|---|---|
| Group I | 194.30 ± 10.58 |
| Group II | 188.94 ± 7.25 |
| Group III | 161.89 ± 14.99**,ΔΔ |
| Group IV | 179.06 ± 11.60*,◊◊ |
| Group V | 182.59 ± 8.21 |
| Group VI | 144.78 ± 19.20**,◊◊,▲▲ |
| Group VII | 174.27 ± 8.94**,☆☆ |
* P < 0.05 versus Group I; ** P < 0.01 versus Group I; ΔΔ P < 0.01 versus Group II; ◊◊ P < 0.01 versus Group III; ▲▲ P < 0.01 versus Group V; ☆☆ P < 0.01 versus Group VI